These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss
1. Dyne reported a quarterly loss of 97 cents per share. 2. Company advances investigational therapies toward potential U.S. acceleration in 2026. 3. Cash runway extended into Q3 2027 to fund clinical milestones. 4. Analysts lowered price targets but maintained positive ratings for DYN. 5. Shares fell 2.5% to $9.08 after earnings announcement.